Peptides commonly discussed in longevity & aesthetics clinics
Learn about the peptides generating the most attention across longevity and aesthetics, why healthcare organizations are watching them, and what current research says about each.
Key takeaways
- Interest is high. Searches for “peptide” rose roughly 398% year over year between June 2025 and July 2026, according to Google Ads Keyword Planner data.¹
- No peptide in this article is FDA-approved for a longevity or aesthetic purpose. Compounded drugs are not FDA-approved, and FDA does not review their safety, effectiveness, or quality before they are marketed.²
- Federal policy changed on October 28, 2026. HHS issued an interim enforcement discretion policy covering six peptides, including MOTS-c, Epitalon, Semax, and KPV, under defined conditions and route-of-administration limits.³,⁴ This is not FDA approval, and it is not formal listing on the 503A Bulks List, which requires rulemaking.
- Human research is limited. Much of the published work on these peptides comes from laboratory and animal studies, and state laws apply in addition to federal policy.⁵
The peptides healthcare organizations are asked about differ widely in how much is known about them. Some have a history of regulated medical use. Others have been studied mainly in laboratory or animal models. For most, human data remain limited.
This article covers peptides that are commonly discussed in longevity and aesthetics practices and that fall within, or are being considered under, current federal compounding policy, following FDA’s July 2026 advisory committee review of compounded peptides. For each, we describe what it is, what published research does and does not show, and its current regulatory status. This is general educational information. It is not a recommendation for or against any treatment.
What are peptides?
Peptides are short chains of amino acids, the building blocks of proteins. By convention, chains of roughly two to 50 amino acids are called peptides, and longer chains are called proteins. Many peptides occur naturally in the body, where they act as signaling molecules that carry instructions between cells.⁶
Some peptides are established medicines. Insulin and the GLP-1 receptor agonists are well-known examples, and more than 80 peptide drugs have been approved worldwide.⁶ Those medicines went through FDA review, with clinical trials supporting specific uses. The peptides in this article are different. None is FDA-approved, and none shares the clinical trial record of those approved drugs.
What does research show about peptides and healthy aging?
Clinicians and researchers have explored peptides in areas such as metabolic function, cognition, sleep, recovery, and skin health. Researchers are also investigating how some peptides may influence biological processes associated with aging. So far, there is no definitive research showing that any peptide produces these outcomes in people.⁵
For most of the peptides discussed here, published human data are limited, early-stage, or retrospective, and well-controlled human trials supporting these purposes are lacking.⁵ No peptide has been shown to extend human lifespan.
Why are peptides drawing so much attention?
According to Google Ads Keyword Planner, searches for “peptide” increased roughly 398% year over year between June 2025 and July 2026, averaging more than 600,000 searches per month.¹ Search volume reflects curiosity, not understanding or evidence.
Federal policy is also moving quickly. FDA’s Pharmacy Compounding Advisory Committee reviewed seven peptides in July 2026, and HHS issued an interim policy in October.³,⁷ HHS has said the policy is meant in part to discourage the continued, widespread use of certain research-use-only peptides, and, in its Federal Register notice, to expand patient access given the lack of approved products.²,⁸
What does “compounded” mean, and why does it matter here?
Compounding is the preparation of a medication tailored to an individual patient by a licensed pharmacist or physician. Under section 503A of the Federal Food, Drug, and Cosmetic Act, a state-licensed pharmacy may prepare a drug for an identified patient based on a valid prescription.⁸ Compounded drugs are not FDA-approved. FDA does not review their safety, effectiveness, or quality before they are marketed.²
How do compounded drugs qualify for 503A exemptions?
To qualify for the 503A exemptions, a compounded drug must be made from a bulk drug substance that meets one of three conditions: it complies with a USP or NF monograph, it is a component of an FDA-approved drug, or it appears on FDA’s 503A Bulks List.³,⁹
The substance must also come from an FDA-registered manufacturer and be accompanied by a certificate of analysis.⁸ While FDA evaluates nominated substances, its interim policy sorts them into categories. For Category 1 substances, FDA has said it does not intend to take action against compounders when the policy’s conditions are met. Category 1 is an enforcement position. It is not approval.⁹
How federal policy works today
Four terms are easy to confuse. Each means something different.
| Term | What it is | What it is not |
| Advisory committee recommendation | On July 23–24, 2026, FDA’s Pharmacy Compounding Advisory Committee (PCAC) voted to recommend six peptides for the 503A Bulks List: BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax.³ | A binding decision. The vote was advisory and non-binding, and FDA staff had proposed listing none of them, citing limited product characterization and human evidence.⁵ |
| HHS interim enforcement discretion | As of October 28, 2026, HHS does not intend to act against state-licensed pharmacies, federal facilities, or licensed physicians that compound the six peptides when the policy’s ten conditions are met (which include route-of-administration limits, single-ingredient products, FDA-registered manufacturers, certificates of analysis, patient-specific prescriptions, and adverse event reporting).³,¹⁰ | FDA approval. It does not cover 503B outsourcing facilities or products sold as research chemicals or dietary supplements, and HHS may revisit it if a safety or quality issue arises. The Federal Register notice published October 30, 2026 opened a public comment period.²,¹⁰ |
| Formal listing on the 503A Bulks List | A permanent addition that requires FDA notice-and-comment rulemaking. | In effect yet. That rulemaking has not happened for these peptides.²,³ |
| FDA approval | A separate process, based on clinical trials of a specific product for a specific use. | In place here. None of the peptides in this article has FDA approval for any longevity or aesthetic purpose. |
State pharmacy and medical practice laws apply in addition to the federal framework. The full list of the six peptides is available in our recent overview.
Peptides and their current regulatory status
Each summary below states whether the research was done in cells, animals, or people, and gives the peptide’s current regulatory status. A summary of research is not a statement that a peptide is safe or effective.
Sermorelin
What is Sermorelin?
Sermorelin is a synthetic peptide made of the first 29 amino acids of growth hormone-releasing hormone (GHRH). It stimulates the pituitary gland to release growth hormone. It is not growth hormone itself.¹¹
What the research shows
Sermorelin has a history in regulated medicine. FDA approved sermorelin acetate products (brand name GEREF) for diagnostic testing of growth hormone secretion and for treating growth hormone deficiency in children. The manufacturer later discontinued them, and FDA determined that the discontinuation was not for reasons of safety or effectiveness.¹² A published review describes sermorelin’s use as a diagnostic test and, based on limited data, in treating some children with idiopathic growth hormone deficiency.¹¹ That research does not establish benefits for healthy adults, and compounded sermorelin is not FDA-approved for any longevity or aesthetic purpose.
Regulatory status
Sermorelin acetate was the active ingredient in GEREF, an FDA-approved drug discontinued for commercial reasons, not safety or efficacy (per FDA). 503A pharmacies compound sermorelin under patient-specific prescriptions on that basis. Compounded sermorelin isn’t FDA-approved and must meet all federal and state compounding requirements.
MOTS-c acetate
The next four peptides are among the six covered by HHS’s interim policy. The other two, BPC-157 and TB-500, are outside the scope of this article.
What is MOTS-c?
MOTS-c is a 16-amino-acid peptide encoded in mitochondrial DNA. It was first described in 2015.¹³
What the research shows
In that original study, MOTS-c treatment in mice was associated with effects on insulin sensitivity and with protection from diet-induced obesity. Published research to date consists largely of cell and animal studies and early human measurements of circulating MOTS-c levels.¹³ This work does not establish that MOTS-c is safe or effective for any use in people. In its July 2026 briefing materials, FDA reported finding little or no human safety and effectiveness data for MOTS-c.⁵
Regulatory status
Within HHS’s interim enforcement discretion policy for subcutaneous or intramuscular injectable dosage forms, when the policy’s conditions are met.⁴ Not FDA-approved. Not on the 503A Bulks List.
Epithalon acetate
What is Epithalon?
Epithalon is a synthetic four-amino-acid peptide (Ala-Glu-Asp-Gly) developed from research on epithalamin, an extract of the pineal gland.¹⁴,¹⁵
What the research shows
Much of the research on epithalamin and epitalon has come from a single research group in St. Petersburg, Russia, over several decades, and independent replication is limited.¹⁴,¹⁵ Some of the lifespan-related findings in that literature, including a reported human cohort, involve epithalamin or epithalamin combined with a thymus peptide, not synthetic epitalon, and should not be read as findings about epitalon itself.¹⁴
A 2025 laboratory study reported effects on telomere length and telomerase-related measures in cultured human cell lines, including breast cancer cell lines, treated with epithalon.¹⁶ That work was done in cells, not patients, and does not show that epitalon affects telomeres or health outcomes in people. The article has since been corrected by the publisher, and readers should consult the correction notice.¹⁷
FDA’s briefing document raised a theoretical concern about cancer risk related to telomerase activation, and FDA reported finding no human safety studies of epitalon.⁵,¹⁸
Regulatory status
Within HHS’s interim enforcement discretion policy for subcutaneous or intramuscular injectable dosage forms dispensed in intermittent courses, when the policy’s conditions are met.⁴ Not FDA-approved. Not on the 503A Bulks List.
Semax (free base)
What is Semax?
Semax is a synthetic seven-amino-acid peptide (Met-Glu-His-Phe-Pro-Gly-Pro) related to a fragment of adrenocorticotropic hormone (ACTH).¹⁹ It was developed in Russia, where it is registered as a medicine. It is not FDA-approved.²⁰
What the research shows
Published laboratory research, such as a rat study, has examined Semax’s effects on brain-derived neurotrophic factor (BDNF) signaling in the hippocampus.¹⁹ That evidence is preclinical. Human data are concentrated in the Russian clinical literature, and Western clinical research is more limited. In July 2026, FDA staff proposed that Semax not be added to the 503A Bulks List, citing among other concerns gaps in product characterization and limited human evidence. The advisory committee voted to recommend it.³,²⁰
Regulatory status
Within HHS’s interim enforcement discretion policy for intranasal use, when the policy’s conditions are met.⁴ Not FDA-approved. Not on the 503A Bulks List.
KPV acetate
What is KPV?
KPV is a three-amino-acid peptide (lysine-proline-valine) that corresponds to the end of alpha-melanocyte-stimulating hormone (alpha-MSH). Researchers have studied its anti-inflammatory effects, mainly in models of gut inflammation.²¹
What the research shows
In one study, KPV reduced inflammatory signaling in human intestinal and immune cell lines and reduced inflammatory markers in two mouse models of colitis.²¹ Those are cell and animal findings. They do not establish that KPV is safe or effective in people with inflammatory bowel disease or any other condition. FDA’s July 2026 briefing document reported finding no information on KPV administered to humans.²²
Regulatory status
Within HHS’s interim enforcement discretion policy for topical and oral dosage forms, when the policy’s conditions are met.⁴ Not FDA-approved. Not on the 503A Bulks List.
GHK-Cu (non-injectable)
What is GHK-Cu (non-injectable)?
GHK-Cu is a complex of copper and the three-amino-acid peptide GHK (glycyl-L-histidyl-L-lysine), which occurs naturally in human plasma.²³ It is also used as an ingredient in cosmetic products.²⁴
What the research shows
Laboratory and animal research, summarized in narrative reviews, has examined GHK-Cu’s role in processes such as collagen synthesis and tissue repair.²³,²⁴ Most human research concerns topical use in dermatology. Evidence for injectable use is more limited, and narrative reviews are not a substitute for controlled clinical trials of compounded products.
Regulatory status
Non-injectable GHK-Cu appears in Category 1 of FDA’s list of bulk drug substances nominated for 503A compounding and may be compounded under FDA’s interim policy for nominated substances when that policy’s conditions are met.⁹,²⁵ This is separate from HHS’s October 2026 policy for the six peptides above, which does not address GHK-Cu. Injectable GHK-Cu is not in Category 1. FDA has said its advisory committee will review GHK-Cu before the end of February 2027.²⁶ Not FDA-approved.
Peptides FDA has announced for 2027 advisory committee review
FDA has announced that its advisory committee will meet again before the end of February 2027 to consider five additional peptides for the 503A Bulks List:
- Cathelicidin (LL-37)
- GHK-Cu
- Dihexa acetate
- Melanotan II
- PEGylated mechano growth factor (PEG-MGF).⁶
As of this writing, FDA has not posted a final meeting date. Being scheduled for advisory committee consideration does not establish compounding eligibility, safety, effectiveness, or likely inclusion on the 503A Bulks List.
Non-injectable GHK-Cu is an exception on eligibility: it appears in Category 1 of FDA’s list of bulk drug substances nominated for 503A compounding and may be compounded under FDA’s interim policy when that policy’s conditions are met.
Injectable GHK-Cu is not in Category 1.¹⁰,²⁴ The other four substances are not covered by HHS’s interim policy and should not be assumed to be available for 503A compounding.⁴
For a broader look at peptides discussed in recovery and performance programs, see our companion article.
5 things healthcare organizations should keep in mind when building a peptide program
The peptide landscape is changing quickly. Organizations considering peptide programs should keep these points in mind:
- Policy can change. HHS may revisit or amend the interim policy, and final rulemaking could change its conditions.²,³
- Sourcing matters. The policy’s conditions reach the supply chain, including FDA-registered manufacturers and certificates of analysis.³ Research-use-only products are outside the policy.¹⁰
- State law applies. State pharmacy and medical practice laws apply in addition to federal policy.
- Claims should match the evidence. Marketing and patient-facing materials should not describe compounded peptides as FDA-approved, cleared, endorsed, or proven, and should not imply guaranteed results. They should describe the evidence accurately, including where it comes from animal or early human studies.
- Documentation matters. Clinical documentation and informed consent should reflect each product’s compounded, non-FDA-approved status.
Organizations should consult qualified legal counsel about their specific obligations.
Build a peptide therapy program with OpenLoop®
Whether additional peptides move through FDA review or remain under evaluation, healthcare organizations face the same challenge: preparing for patient interest while building programs designed to adapt as federal and state requirements change.
A program needs clinical protocols, clinician networks, pharmacy partnerships, patient workflows, and technology, along with ongoing compliance monitoring.
OpenLoop’s virtual care infrastructure is built to support healthcare organizations launching and scaling peptide programs, whether you are expanding an existing offering or exploring peptide therapy for the first time.
Learn more about how to offer a peptide therapy program for your business.
Compounded drugs are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or quality. The peptides discussed in this article have not been approved by FDA for any longevity or aesthetic use. A prescription is issued only after evaluation by a licensed clinician and only when clinically appropriate.
This content is for general informational purposes only. It is not medical or legal advice and does not create a clinician-patient or attorney-client relationship. For guidance on your specific situation, consult a licensed clinician or attorney.
References
- Google Ads Keyword Planner. Search volume for the keyword “peptide,” June 2025–July 2026. Internal export on file with OpenLoop Marketing.
- U.S. Department of Health and Human Services. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (notice of availability). Federal Register Doc. 2026-22192, published October 30, 2026. https://www.federalregister.gov/documents/2026/10/30/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances
- McDermott Will & Schulte. Peptides first, paperwork later: HHS clears six for compounding ahead of bulks list rulemaking. https://www.mcdermottlaw.com/insights/peptides-first-paperwork-later-hhs-clears-six-for-compounding-ahead-of-bulks-list-rulemaking/
- U.S. Department of Health and Human Services. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, Appendix B (substance identity and permitted routes of administration). https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf
- U.S. Food and Drug Administration. Briefing Document, Pharmacy Compounding Advisory Committee Meeting, July 23–24, 2026 (introduction and substance-specific briefing documents). https://www.fda.gov/media/193342/download
- Muttenthaler M, King GF, Adams DJ, Alewood PF. Trends in peptide drug discovery. Nat Rev Drug Discov. 2021;20(4):309-325.
- U.S. Food and Drug Administration. July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- U.S. Department of Health and Human Services. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (policy text). https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy.pdf
- U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act (describes the statutory conditions and the interim policy categories). https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act
- BakerHostetler (via Lexology). HHS Issues Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. https://www.lexology.com/library/detail.aspx?g=60e6b7a9-bf1f-4e8d-be3e-959707709e4d
- Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999;12(2):139-157. PMID 18031173. https://pubmed.ncbi.nlm.nih.gov/18031173/
- U.S. Food and Drug Administration. Determination That GEREF (Sermorelin Acetate) Injection Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness. 78 Fed. Reg. 14095 (March 4, 2013).
- Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-454. PMID 25738459. https://pubmed.ncbi.nlm.nih.gov/25738459/
- Khavinson VKh, Morozov VG. Peptides of pineal gland and thymus prolong human life. Neuro Endocrinol Lett. 2003;24(3-4):233-240. PMID 15452611. https://pubmed.ncbi.nlm.nih.gov/15452611/
- Khavinson VKh, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med. 2003;135(6):590-592. PMID 12937682. https://pubmed.ncbi.nlm.nih.gov/12937682/
- Al-Dulaimi S, Thomas R, Matta S, Roberts T. Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology. 2025;26(5):178. PMID 40908429. https://pubmed.ncbi.nlm.nih.gov/40908429/
- Correction to: Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology. 2025 Nov 15;27(1):1. PMID 41240216. https://pubmed.ncbi.nlm.nih.gov/41240216/
- Drug Topics. FDA panel to evaluate 7 popular peptides for compounding substances list (summary of FDA briefing documents). https://www.drugtopics.com/view/fda-panel-to-evaluate-7-popular-peptides-for-compounding-substances-list
- Dolotov OV, Karpenko EA, Inozemtseva LS, et al. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Res. 2006;1117(1):54-60. PMID 16996037. https://pubmed.ncbi.nlm.nih.gov/16996037/
- U.S. Food and Drug Administration. Briefing Document: Semax-Related Bulk Drug Substances, Pharmacy Compounding Advisory Committee, July 24, 2026. https://www.fda.gov/media/193348/download
- Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-178. PMID 18061177. https://pubmed.ncbi.nlm.nih.gov/18061177/
- U.S. Food and Drug Administration. Briefing Document: KPV-Related Bulk Drug Substances, Pharmacy Compounding Advisory Committee, July 23, 2026. https://www.fda.gov/media/193346/download
- Pickart L. The human tri-peptide GHK and tissue remodeling. J Biomater Sci Polym Ed. 2008;19(8):969-988. PMID 18644225. https://pubmed.ncbi.nlm.nih.gov/18644225/
- Pickart L, Vasquez-Soltero JM, Margolina A. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. Biomed Res Int. 2015;2015:648108. PMID 26236730. https://pmc.ncbi.nlm.nih.gov/articles/PMC4508379/
- U.S. Food and Drug Administration. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the FD&C Act (list updated May 14, 2026). https://www.fda.gov/media/94155/download
- U.S. Food and Drug Administration. Meeting of the Pharmacy Compounding Advisory Committee (announcement of a meeting before the end of February 2027). https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/meeting-pharmacy-compounding-advisory-committee
